GLP-1 Peptide Atlas, by Delfa

← Trials/Trial dossier/NCT01232946

CompletedPhase NAResults posted

Cooperation of Insulin and GLP-1 on Myocardial Glucose Uptake

Lead sponsor

Indiana University

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

actual

Study population

Obesity / overweight, Type 2 diabetes

Key I/E criteria

•BMI ≥25•HbA1c 7-10%

Primary endpoints

•Myocardial glucose uptake pet•Myocardial Fatty Acid Oxidation Rate•Myocardial Fatty Acid Esterification Rate

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01232946

Org study ID1105005578

Timeline

Milestones

Study first posted2010-11-02estimated

Primary completion2017-09-08actual

Study completion2017-09-08actual

Last update posted2019-08-07actual

Results first posted2019-08-07actual

Study start2012-01 (month precision)

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Obesity / overweightType 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years

Maximum age50 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Type 2 diabetic

•18-50 years

•BMI > 25kg/m2

•HbA1c 7.0-10.0%

•Treated with up to 2 oral agents

Exclusion criteria

•Chronic illness or infection (other than diabetes mellitus)

•Known coronary artery disease, structural heart disease or abnormal ECG on screen.

•Treatment with >2 antihypertensive agents or blood pressure >140/95 on two occasions during screening

•History of claustrophobia, musculoskeletal or other factors which would result in an inability to comfortably remain within the PET scanner gantry for the duration of the imaging protocol.

•Occupational, investigational or other known radiation exposure which together with the planned radiologic studies, will result in greater than 500 mrem total exposure in a 12 month period.

•Current pregnancy

•Treatment with GLP-1 agonist or DPP4 inhibitor within the past 6 months

•Known intolerance to GLP-1 agonist

•Personal history of pancreatitis, personal or family history of medullary thyroid carcinoma, or other contraindications to liraglutide treatment.

•Recognized microvascular complications (neuropathy, nephropathy, retinopathy).

Endpoints (6)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other (unclassified)

Cardiovascular outcomes

Cardiometabolic biomarkers

Cardiovascular outcomes

2 endpoints

Primary/registry result

Myocardial Glucose Uptake

Time frame:3 months

myocardial glucose uptake pet

change from baseline, improvement

Posted result

Group	Value (median), umol/g/min	95% CI
Iiraglutide	0.055	0.0186 – 0.1047
Insulin Detemir	0.0399	0.0129 – 0.0494
Liraglutide Plus Insulin Detemir	0.0373	0.0085 – 0.0455

p0.65Kruskal-Wallis

Primary/registry result

Myocardial Fatty Acid Esterification Rate

Time frame:3 months

change from baseline, descriptive

Posted result

Group	Value (median), umol/g/min	95% CI
Iiraglutide	0.00274	0.00236 – 0.01234
Insulin Detemir	0.00358	0.00249 – 0.00917
Liraglutide Plus Insulin Detemir	0.00146	0.00038 – 0.00863

p0.80Kruskal-Wallis

Cardiometabolic biomarkers

1 endpoint

Primary/registry result

Myocardial Fatty Acid Oxidation Rate

Time frame:3 months

change from baseline, descriptive

Posted result

Group	Value (median), umol/g/min	95% CI
Iiraglutide	0.1019	0.0803 – 0.1399
Insulin Detemir	0.1234	0.0711 – 0.1836
Liraglutide Plus Insulin Detemir	0.0992	0.0801 – 0.1352

p0.065Kruskal-Wallis

Other (unclassified)

3 endpoints

Primary/protocol endpoint/low confidence

Myocardial Glucose Uptake

Time frame:3 months

descriptive

Primary/protocol endpoint/low confidence

Myocardial Fatty Acid Oxidation Rate

Time frame:3 months

descriptive

Primary/protocol endpoint/low confidence

Myocardial Fatty Acid Esterification Rate

Time frame:3 months

descriptive

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Combination GLP-1 and Insulin Treatment Fails to Alter Myocardial Fuel Selection vs. Insulin Alone in Type 2 Diabetes.
The Journal of clinical endocrinology and metabolism2018 Sep 1PMID30020461doi:10.1210/jc.2018-00712via clinicaltrials gov reference derived + pubmed nct search

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableClinicalTrials.gov results section

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.